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Background: To evaluate the effectiveness and tolerability of add-on sitagliptin in elderly Taiwanese
patients with Type 2 diabetes mellitus who have inadequate glycemic control to existing oral antidiabetic
agents (OADs) combination regimens.
Methods: Patients were randomized to receive the existing OAD combinations or add-on with sitagliptin
(100 mg daily) for 24 weeks. We measured HbA1c, fasting plasma glucose, 2-hours postprandial plasma
glucose, body mass index, and recorded the hypoglycemic episodes before and after 24 weeks of adding
sitagliptin 100 mg once daily to existing maximal dose of OAD combination therapy for 24 weeks.
Results: Compared with the change of 0.0% (95% conﬁdence interval: 0.6% to 0.5%) from a baseline of
10.0% in the controlled arm, HbA1c change from a mean baseline of 9.5% was 1.14% 1.18 after add-on
sitagliptin. Conﬁrming signiﬁcant differences (p< 0.0001), sitagliptin was generally well tolerated in all
study patients. The between-groups difference in body mass index was not signiﬁcant after 24 weeks of
treatment.
Conclusion: In elderly Taiwanese patients with Type 2 diabetes mellitus with inadequate glycemic control
from OAD combination, the addition of sitagliptin provided signiﬁcant HbA1c lowering the efﬁcacy over
24 weeks.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Background
The management of elderly patients with Type 2 diabetes mel-
litus (T2DM) has become more complicated because of age-related
physiological changes1,2. In this population, the use of pharmaco-
logical agents also become more difﬁcult as the pancreatic b-cell
function declines over time together with the altered kidney and
hepatic functions. Combination use of multiple antidiabetic drugs
often are required to help these patients to reach the goal because
of the progressive nature of the disease3,4. There is limited data
regarding the use of pharmacologic agents in older adults with
T2DM. The use of recently available newer antidiabetic agents
dipeptidyl peptidase-4 (DPP-4) inhibitors is attractive because of the
desirable characteristics, including once-daily dosing and minimal
risk of hypoglycemiawhen used asmonotherapy5,6. Sitagliptin is thement of Endocrinology and




iwan Society of Geriatric Emergenonly approved DPP-4 inhibitor in Taiwan. By inhibiting the DPP-4,
sitagliptin enhances the incretin axis resulting in an increase in
insulin synthesis and release and decrease glucagon secretion in
a glucose-dependent manner. Sitagliptin is effective as mono-
therapy7e9, as initial combination therapy with metformin10, and as
dual or triple combination with oral antihyperglycemic agents11.
Safety and tolerability have been demonstrated in clinical trials up to
2 years, with a low risk of hypoglycemia during monotherapy or
whenused in combinationwith other antidiabetic agents not known
to cause hypoglycemia12. Clinical data regarding sitagliptin use in
elderly patients are limited13,14. The present study examined the
effectiveness and tolerability of add-on sitagliptin in elderly T2DM
patients with inadequate control to existing oral antidiabetic agent
(OAD) combination regimens.2. Study Methods and Procedures
2.1. Study design and patients
This was a 24-week, randomized, open-labeled, parallel-group
study. Eligible patients were male or female, older than 65 years,cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient demographics and clinical characteristicsa





Age (yr) 73.5 (5.9) 72.5 (5.2) 0.3571
Female (%) 63.3 52.1 0.2650
Duration of DM 13.2 (5.6) 14.2 (4.1) 0.3461
BMI (kg/m2) 26.2 (2.2) 26.0 (2.3) 0.5498
FPG (mg/dL) 222.2 (33.2) 230.5 (31.5) 0.2127
PPG (mg/dL) 292.3 (65.0) 281.8 (74.1) 0.4600
HbA1c (%) 9.5 (1.3) 10.0 (1.6) 0.1040
BMI¼ Body mass index; DM¼ diabetes mellitus; FPG¼ fasting plasma glucose;
PPG¼ postprandial glucose; QD¼ once a day; SD¼ standard deviation.
a Data are expressed as mean SD or number of patients (%).
Table 2
Mean changes from baseline of FPG, PPG, HbA1C, and goal attainmenta
Parameters Sitagliptin 100 mg QD Control
FPG (mg/dL)
Baseline vs. Week 12 29.0 (39.9, 19.1)b 2.2 (8.8, 4.3)
Baseline vs. Week 24 38.3 (53.4, 23.1)b 6.8 (19.9, 6.3)
12 wk vs. Week 24 9.3 (24.5, 6.0) 4.6 (17.7, 8.5)
PPG (mg/dL)
Baseline vs. Week 12 45.0 (62.7, 27.3)b 9.0 (20.0, 2.0)
Baseline vs. Week 24 60.0 (78.6, 41.3)b 15.2 (46.2, 15.8)
12 wk vs. Week 24 15.0 (37.2, 7.2) 6.1 (35.3, 23.0)
HbA1c (%)
Baseline vs. Week 12 1.0 (1.3, 0.7)b 0.0 (0.2, 0.1)
Baseline vs. Week 24 1.1 (1.5, 0.8)b 0.0 (0.6, 0.5)
12 wk vs. Week 24 0.2 (0.5, 0.2) 0.0 (0.5, 0.5)
LS mean change of HbA1c (%)c
Baseline vs. Week 12 1.0 (1.3, 0.8) 0.0 (0.2, 0.3)
Baseline vs. Week 24 1.3 (1.6, 0.9) 0.1 (0.3, 0.5)
The achievement of treatment goal (<7%) of HbA1c (%)d
Baseline 0 (0.0) 0 (0.0)
Week 24 13 (26.5) 0 (0.0)
ANCOVA¼ analysis of covariance; BMI¼ body mass index; FPG¼ fasting plasma
glucose; PPG¼ postprandial glucose; QD¼ once a day; SD¼ standard deviation.
a Data are expressed as mean (95% conﬁdence interval) or least square mean (95%
conﬁdence interval).
b The p value is less than 0.0001 and tested by paired t test.
c The p value is less than 0.0001 and tested by repeat measure ANCOVA.
d The p value is less than 0.0001 and is tested by c2 at Week 24.
M.-N. Chien et al104taking OAD combinations (sulfonylurea, metformin, and alpha-
glucosidase inhibitors) therapy but had inadequate response as
determined by HbA1c level of 7% or higher. Patients were excluded
if they had any signiﬁcant diseases that were likely to affect the
outcome and compliance of this study. Such diseases or conditions
included heart failure, hepatic dysfunction, renal insufﬁciency
with a creatinine level of 1.5 mg/dL or higher, and use of insulin
pumps. Patients who had received any educational program for
diabetes management from elsewhere other than ours were also
excluded. Written informed consent was obtained from each
participant.
Patients were randomized to continue their existing OAD
combinations or add-on with sitagliptin (100 mg daily) for 24
weeks. We measured HbA1c, fasting plasma glucose (FPG), 2-hours
postprandial plasma glucose (PPG), body mass index (BMI), and
recorded the hypoglycemic episodes and other adverse event (AE)
at baseline, Week 12, and Week 24 during the study period.
Participants in the both groups visited our medical doctors at least
three times during the 24-weeks study period. All study patients
were provided with disease education and treatment information,
dosing regimen, lifestyle modiﬁcation, and so on by the trained
specialists in our outpatient department during each follow up
visit. A more individualized and detailed information about diet
recommendation and lifestyle modiﬁcation were also given by
dietician on as needed basis.
2.2. Evaluations
The primary endpoint was the percent changes of HbA1c
between two groups after 24 weeks of treatment. Other efﬁcacy
endpoints included FPG and 2-hour PPG. Body weight was
measured at baseline, Week 12, and Week 24. Safety and tolera-
bility were assessed by collecting the AEs.
2.3. Statistical methods
Student t test was used for within-group comparison, analysis of
covariance was used to adjust baseline HbA1c values for between-
group comparison, a p value less than 0.05 was considered to be
signiﬁcant.
3. Results
One hundred ten elderly patients with T2DM were screened,
13 patients were not randomized because of failure to meet gly-
cemic inclusion criteria at baseline. All randomized patients who
received at least one dose of study drug were included in the data
analysis. The two treatment groups were generally well balanced
with respect to baseline demographics and disease characteristics
(Table 1). Mean age (standard deviation) was 73.5 (5.9) in sita-
gliptin group and 72.5 (5.2) in the control group; mean diabetes
duration was 13.7 years in both groups. All patients were
receiving OAD combinations (sulfonylurea, metformin, and alpha-
glucosidase inhibitors) therapy, with HbA1c level of 7% or higher
(mean HbA1c levels: 9.5% in sitagliptin group and 10.0% in control
group).
The addition of sitagliptin 100 mg to existing OAD combination
regimens signiﬁcantly reduced HbA1c (1.3%), FPG (38.3 mg/dL),
and PPG (60.0 mg/dL) (all p< 0.0001) at 24 weeks compared with
baseline value but no signiﬁcant reductions in these parameters
were found in the control group (Table 2 and Fig. 1). The least
square mean change of HbA1c from baseline between groups at
Week 24 was also signiﬁcantly different (p< 0.0001). At Week 24,
an additional 26.5% patients in the sitagliptin group achieved the
treatment goal of HbA1c level of 7% or less.Sitagliptin was generally well tolerated in all study patients. The
between-groups difference in BMI was not signiﬁcant after 24
weeks of treatment (Table 3), which indicated no increase in body
weight after add-on sitagliptin. Only one hypoglycemic episode
was reported in the sitagliptin group. No signiﬁcant differences
were observed between groups regarding the overall incidences of
AEs, drug-related AEs, serious AEs, serious drug-related AEs, and
study discontinuations because of AEs (Table 4).
4. Discussion
T2DM can be complicated and difﬁcult to treat in elderly
patients. Glycemic goals in elderly patients and interventions to
achieve such goals must take into account the clinical status of
individual patients to avoid unexpected comorbidities. Balance
between achieving glycemic goals and avoiding hypoglycemia can
be a challenge as advanced age itself can contribute to the risk of
hypoglycemia because hypoglycemia can have a profound impact
on health outcomes and quality of life in elderly patients. Unfor-
tunately, recognition of hypoglycemia may be diminished in the
elderly, the warning symptoms of hypoglycemia, such as shaky,
weak, sweating, or hungry complaints may be absent or diminished
with autonomic neuropathy. Existing antidiabetic regimens thus
Fig. 1. Comparison of key glycemic indices over time in patients treated with either
sitagliptin or existing OAD combinations (control). (A) HbA1c and (B) FFG and PPG. All
values are mean standard error. For HbA1c, least-square mean change was p value
less than 0.0001; for FPG and PPG, *p value less than 0.0001 was tested by paired t test.
FPG¼ fasting plasma glucose; PPG¼ postprandial glucose.
Table 4
Clinical AE reported during the 24-wk study period




Number of patients reporting AE 5 3
Number of AEs reported 5 3





Low back pain 1 0
Hypoglycemia 1 0
Diarrhea 0 1
Number of serious AEs reported 0 0
AE¼ adverse experience; QD¼ once a day; URI¼ upper respiratory tract infection;
UTI¼ urinary tract infection.
Elderly Type 2 Diabetes and Sitagliptin 105pose increased risk for hypoglycemia in the elderly patients. On the
other hand, because of the progressive nature of T2DM, there are
many patients who do not achieve glycemic control only by OAD,
insulin may provide additional glycemic beneﬁts, but in practice,
patients and physicians are often resistant to this approach because
of various factors, including an increased risk of hypoglycemia or
weight gain and practical barriers to insulin therapy adjustments15.
The new incretin-based therapies offer advantages over standard
medications by improving glucose-dependent insulin secretion.
Barnett16 reported that the oral gliptins can be combined with
other OADs and also with insulin, whereas the most important
combination is with metformin, and one of its most important
beneﬁts is its lack of weight gain17.
All our study patients had received combination regimens of
metformin, alpha-glucosidase inhibitors, and sulfonylurea, which
are the most commonly used drug classes prescribed in T2DM; but
often being associated with weight gain and hypoglycemic episode,Table 3
BMI (kg/m2) at baseline, Week 12, and Week 24
BMI Sitagliptin, mean (95% CI) Control, mean (95% CI) p
Baseline 26.3 (25.7, 27.0) 26.1 (25.4, 26.7) 0.5498
12 wk 26.1 (25.6, 26.6) 26.1 (25.6, 26.6) 0.9578
24 wk 26.2 (25.8, 26.6) 26.0 (25.6, 26.5) 0.5498
BMI¼ body mass index; CI¼ conﬁdence interval.especially in elderly patients, the fears of AE often lead to
noncompliance in medication and lifestyle modiﬁcation, which, in
turn, led to poor glycemic control and failure to achieve treatment
goal.
In the present study, clinical AEs of hypoglycemia, selected
gastrointestinal events (diarrhea), upper respiratory tract infection,
and urinary tract infection, as well as BMI changes were pre-
speciﬁed as AEs of interest and were observed closely throughout
the study period. Sitagliptin was shown to be well tolerated, the
incidence of hypoglycemia was similarly low (0%e2%) between
both treatment groups, with no episode of hypoglycemia exhibit-
ing marked severity, although Williams-Herman et al12 reported
that sitagliptin was generally well tolerated with an overall inci-
dence of AEs comparable with placebo, a low risk of hypoglycemia
or gastrointestinal AEs, and a neutral effect on body weight.
Charbonnel B et al18 and Gagliardino et al19 all stated that because
metformin reduces hepatic glucose production and increases
glucagon-like peptide 1 release, combined therapy of metformin
and sitagliptin provides complementary and additive effects
through regulating the glucose-dependent insulin secretion and
suppression of glucagon concentrations, with no signiﬁcant
increase in AEs of hypoglycemia. However, when exogenous insulin
that is not regulated by ambient glucose or incretin is added, the
incidence of hypoglycemia may not be unexpected with the
addition of sitagliptin to the treatment regimens. Different rates of
hypoglycemia have been reported with DPP-4 inhibitors when
added to ongoing OAD or insulin therapy. Pratley et al6 had also
reported the experience of alogliptin used in elderly people
showing improvements in HbA1c similar to those seen in younger
patients, and no increase in the risk of hypoglycemia, weight gain,
or other AEs. The differences across studies may be related to study
population, including different age and race, years of diabetes
duration, entry criteria, baseline HbA1c/FPG, dose and regimen,
responses to treatment, and importantly, the different deﬁnitions
of hypoglycemia.
In our study, sitagliptin also demonstrated a neutral effect on
body weight after 24 weeks of treatment. The improvements of
glycemic control both in the fasting and postprandial states were
not accompanied by an increase in body weight relative to the
control group. We believe that the glucose-dependent mechanism
of DPP4 inhibitor may contribute to increase medication compli-
ance and diet control and break the vicious cycle mentioned above
after taking the conventional antidiabetic medication.
There are several limitations to the present study. First, as an
open-labeled study, a placebo effect may exist that can be neither
be discounted nor estimated. However, the bias are less likely to
occur in the efﬁcacy endpoints of this study, which were deter-
mined through laboratory tests but may more likely occur in the
M.-N. Chien et al106safety evaluation by knowing the changes in treatment regimen.
Second, the number of subjects was too small to be stratiﬁed for
subgroup analysis according to patients’ baseline HbA1c levels;
therefore, we could not analyze the association between glycemic
variables and efﬁcacy/impact of sitagliptin treatment. Third, the
duration of our study was short, further clinical studies are
necessary to evaluate the long-term effects of sitagliptin as add-on
therapy for elderly patients with T2DM. Future clinical studies
should evaluate whether this add-on therapy has the potential to
delay progression or prevent elderly T2DM.
In conclusion, our study in Taiwanese elderly patients with
T2DM with inadequate glycemic control from OAD combination,
the addition of sitagliptin provided signiﬁcant HbA1c lowering
efﬁcacy over 24 weeks.References
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